Key clinical point: Golimumab reduced disease activity and improved work productivity, activity, and the quality of life (QoL) in patients with psoriatic arthritis (PsA).
Major finding: At 24 months after golimumab initiation, there was significant decrease in mean Clinical Disease Activity Index (−21.7; P < .0001), along with improvement in total work productivity impairment ( P = .0186), presenteeism ( P = .0007), activity impairment ( P < .0001), and mean QoL (−8.3; P < .0001) scores.
Study details: Findings are from a prospective study including patients with PsA (n = 69), rheumatoid arthritis (n = 95), and axial spondyloarthritis (n = 69) who initiated golimumab; of these 110 patients were followed-up for 24 months.
Disclosures: This study was funded by MSD Austria. The authors declared no conflicts of interest.
Source: Dejaco C et al. A prospective study to evaluate the impact of golimumab therapy on work productivity and activity, and quality of life in patients with rheumatoid arthritis, psoriasis arthritis and axial spondyloarthritis in a real life setting in Austria: The GO-ACTIVE study. Front Med. 2022;9:881943 (Jun 2). Doi: 10.3389/fmed.2022.881943